Praxis Precision (PRAX) announced that the FDA has accepted for review its new drug application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor in adults. The FDA has set a target action date under the Prescription Drug User Fee Act of January 29, 2027 and is not planning to hold an advisory committee meeting.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Advancing CNS Pipeline and Near-Term Data Catalysts Support Buy Rating Despite Cash Burn
- Praxis Precision initiated with a Strong Buy at Raymond James
- 3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
- Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward
- Praxis reports positive elsunersen trial in pediatric epilepsies